Multiple sclerosis

Long term data confirms relapse benefit of DMTs in MS

Continued treatment with disease-modifying therapies (DMTs) significantly reduces relapses and disability accrual in the long term for patients with relapsing-remitting MS. A study using data from 14, 717 patients in the international MSBase Neuroimmunology Registry found relapses reduced by about 40% (HR 0.60; p = 0.0016) in a “pseudo cohort” of patients continuously treated with ...

Already a member?

Login to keep reading.

© 2021 the limbic